MX2025001041A - Anticuerpos anti-tl1a para el tratamiento de la colitis ulcerosa y la enfermedad de crohn - Google Patents
Anticuerpos anti-tl1a para el tratamiento de la colitis ulcerosa y la enfermedad de crohnInfo
- Publication number
- MX2025001041A MX2025001041A MX2025001041A MX2025001041A MX2025001041A MX 2025001041 A MX2025001041 A MX 2025001041A MX 2025001041 A MX2025001041 A MX 2025001041A MX 2025001041 A MX2025001041 A MX 2025001041A MX 2025001041 A MX2025001041 A MX 2025001041A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- crohn
- ulcerative colitis
- tl1a antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263369591P | 2022-07-27 | 2022-07-27 | |
| US202263387786P | 2022-12-16 | 2022-12-16 | |
| PCT/US2023/071103 WO2024026395A1 (en) | 2022-07-27 | 2023-07-27 | Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025001041A true MX2025001041A (es) | 2025-04-02 |
Family
ID=87747839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025001041A MX2025001041A (es) | 2022-07-27 | 2025-01-24 | Anticuerpos anti-tl1a para el tratamiento de la colitis ulcerosa y la enfermedad de crohn |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250270336A1 (https=) |
| EP (1) | EP4562040A1 (https=) |
| JP (1) | JP2025526402A (https=) |
| KR (1) | KR20250044336A (https=) |
| CN (1) | CN119894931A (https=) |
| AU (1) | AU2023314783A1 (https=) |
| CA (1) | CA3262839A1 (https=) |
| CL (1) | CL2025000202A1 (https=) |
| IL (1) | IL318428A (https=) |
| MA (1) | MA71621A (https=) |
| MX (1) | MX2025001041A (https=) |
| WO (1) | WO2024026395A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| KR101982899B1 (ko) | 2011-09-30 | 2019-05-27 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | ＴＬ1ａ에 대한 항체 및 그의 용도 |
| US9683998B2 (en) * | 2013-11-13 | 2017-06-20 | Pfizer Inc. | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| PL3774897T3 (pl) * | 2018-04-30 | 2024-01-29 | Cedars-Sinai Medical Center | Sposoby i układ do selekcji i leczenia pacjentów z chorobami zapalnymi |
| AU2020275413A1 (en) * | 2019-05-14 | 2021-12-23 | Cedars-Sinai Medical Center | TL1A patient selection methods, systems, and devices |
| WO2021034639A1 (en) * | 2019-08-16 | 2021-02-25 | Regeneron Pharmaceuticals, Inc. | High concentration anti-c5 formulations |
| BR112022025667A2 (pt) | 2020-06-26 | 2023-03-07 | Pfizer | Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a |
-
2023
- 2023-07-27 KR KR1020257006034A patent/KR20250044336A/ko active Pending
- 2023-07-27 EP EP23757805.9A patent/EP4562040A1/en active Pending
- 2023-07-27 AU AU2023314783A patent/AU2023314783A1/en active Pending
- 2023-07-27 WO PCT/US2023/071103 patent/WO2024026395A1/en not_active Ceased
- 2023-07-27 MA MA71621A patent/MA71621A/fr unknown
- 2023-07-27 JP JP2025504350A patent/JP2025526402A/ja active Pending
- 2023-07-27 CN CN202380060940.7A patent/CN119894931A/zh active Pending
- 2023-07-27 IL IL318428A patent/IL318428A/en unknown
- 2023-07-27 CA CA3262839A patent/CA3262839A1/en active Pending
-
2025
- 2025-01-23 CL CL2025000202A patent/CL2025000202A1/es unknown
- 2025-01-23 US US19/035,531 patent/US20250270336A1/en active Pending
- 2025-01-24 MX MX2025001041A patent/MX2025001041A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL318428A (en) | 2025-03-01 |
| CN119894931A (zh) | 2025-04-25 |
| KR20250044336A (ko) | 2025-03-31 |
| CA3262839A1 (en) | 2024-02-01 |
| AU2023314783A1 (en) | 2025-03-06 |
| US20250270336A1 (en) | 2025-08-28 |
| JP2025526402A (ja) | 2025-08-13 |
| EP4562040A1 (en) | 2025-06-04 |
| MA71621A (fr) | 2025-05-30 |
| WO2024026395A1 (en) | 2024-02-01 |
| CL2025000202A1 (es) | 2025-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202204557B (en) | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof | |
| MX2022013163A (es) | Anticuerpo contra nectin-4 y aplicacion del mismo. | |
| FI4175951T3 (fi) | Hpk1-estäjiä ja niiden käyttötapoja | |
| MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
| MA39070A1 (fr) | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains | |
| MA47313A (fr) | Formulations sous-cutanées d'anticorps her2 | |
| US20120213805A1 (en) | Amatoxin-Armed Tartget-Binding Moieties for the Treatment of Cancer | |
| RU2008141171A (ru) | Анти-тат226 антитела и иммуноконъюгаты | |
| CO4850562A1 (es) | Proceso para producir una preparacion concentrada de anticuerpos | |
| JP2022515077A5 (https=) | ||
| EA200101064A1 (ru) | Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами | |
| MX2025001041A (es) | Anticuerpos anti-tl1a para el tratamiento de la colitis ulcerosa y la enfermedad de crohn | |
| ZA200609407B (en) | Monoclonal antibodies to hepatocyte growth factor | |
| MX2023009622A (es) | Composiciones que comprenden anticuerpos humanizados contra ligandos de tipo tnf 1a (tl1a) y sus usos. | |
| JP2016063817A5 (https=) | ||
| WO2020023644A3 (en) | Antibody directed against s. aureus clumping factor a (clfa) | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
| WO2021259927A3 (en) | Anti-cd2 antibodies | |
| KR960010024A (ko) | 류머티즘 치료제 | |
| JP2025148452A5 (https=) | ||
| Cui et al. | Cirmtuzumab vedotin (UC-961ADC3), an anti-ROR1-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for ROR1-positive leukemia and solid tumors | |
| WO2021056025A3 (en) | Anti-epha10 antibodies and methods of use thereof | |
| MX2025001452A (es) | Anticuerpos anti-ccr8 y metodos de uso | |
| MX2023010764A (es) | Anticuerpo anti componente del complemento 1s (c1s). |